Artgen Biotech PJSC (MIC:ABIO) Marketable Securities: ₽5 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIC:ABIO Artgen Biotech PJSC MIC:ABIO
17 GF Score
Price ₽44.46
View Full Analysis

What is Artgen Biotech PJSC Marketable Securities?

Artgen Biotech PJSC MIC:ABIO +0.50% 17 Marketable Securities is ₽5 Mil as of Jun. 2023. GuruFocus rates MIC:ABIO with a GF Score™ of 17/100.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Artgen Biotech PJSC's Marketable Securities for the quarter that ended in Jun. 2023 was ₽5 Mil.

Artgen Biotech PJSC's annual Marketable Securities increased from Dec. 2020 (₽20 Mil) to Dec. 2021 (₽25 Mil) and increased from Dec. 2021 (₽25 Mil) to Dec. 2022 (₽81 Mil).

Artgen Biotech PJSC  (MIC:ABIO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Artgen Biotech PJSC Marketable Securities Related Terms

Artgen Biotech PJSC Marketable Securities Historical Data

* Premium members only.

The historical data trend for Artgen Biotech PJSC's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artgen Biotech PJSC Marketable Securities Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 140.56 100.43 19.80 25.15 80.95

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.10 25.15 62.07 80.95 5.40
MIC:ABIO
17GF Score
Artgen Biotech PJSC MIC:ABIO
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artgen Biotech PJSC Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₽5 Mil mean?
Artgen Biotech PJSC (MIC:ABIO) has a Marketable Securities of ₽5 Mil as of Jun. 2023. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Artgen Biotech PJSC and its competitors.
Is Artgen Biotech PJSC's Marketable Securities too high?
Artgen Biotech PJSC's current Marketable Securities is ₽5 Mil. Overall, Artgen Biotech PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Artgen Biotech PJSC's Marketable Securities compare to VRTX and REGN?
Artgen Biotech PJSC's Marketable Securities of ₽5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Artgen Biotech PJSC and its competitors. Artgen Biotech PJSC's current Marketable Securities is ₽5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artgen Biotech PJSC stock overvalued right now?
Artgen Biotech PJSC (MIC:ABIO) has a current Marketable Securities of ₽5 Mil. The current Marketable Securities is ₽5 Mil. Artgen Biotech PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Artgen Biotech PJSC (MIC:ABIO), the current Marketable Securities is ₽5 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artgen Biotech PJSC Business Description

Address Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.
17GF Score

Get the complete analysis for MIC:ABIO

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽44.46
Price